New insider activity at Quest Diagnostics ( (DGX) ) has taken place on February 22, 2025.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
In recent stock transactions involving Quest Diagnostics, EVP of Regional Businesses Catherine Doherty sold 535 shares, amounting to $90,794. Meanwhile, SVP for Diagnostic Services Patrick Plewman sold 320 shares, valued at $54,307.
Recent Updates on DGX stock
Quest Diagnostics has recently announced a partnership with Grail to offer the Galleri multi-cancer early detection test, leveraging Quest’s extensive network to increase accessibility in the U.S. This strategic move comes amid Quest’s strong Q4 earnings report, which highlighted robust revenue growth driven by strategic acquisitions and expansions in Advanced Diagnostics. Analysts have responded positively, with firms like Mizuho and Piper Sandler raising price targets due to Quest’s high earnings visibility, market share gains, and expansion into higher margin testing areas. Despite challenges such as weather impacts and pricing pressures in the hospital segment, Quest remains optimistic about future growth, supported by consumer testing improvements and operational efficiencies.
More about Quest Diagnostics
YTD Price Performance: 14.67%
Average Trading Volume: 925,438
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $19.21B